CST, 3751S, Phospho-SHP-2 (Tyr542) Antibody

Polyclonal Antibody for studying SHP-2 (Tyr546) phosphate. Validated for Western Blotting,Simple Western™,Immunoprecipitation. Available in 2 sizes. Highly specific and rigorously validated in-house, Phospho-SHP-2 (Tyr542) Antibody (CST #3751) is ready to ship. Product Usage Information Western Blotting: 1:1000 Simple Western™: 1:50 - 1:250 Immunoprecipitation: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity Phospho-SHP-2 (Tyr542) Antibody detects endogenous levels of SHP-2 only when phosphorylated at Tyr542. This antibody may cross-react with activated receptor tyrosine kinases. Species Reactivity: Human, Mouse, Rat Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr542 of human SHP-2 protein. Antibodies are purified by protein A and peptide affinity chromatography. Background SHP-2 (PTPN11) is a ubiquitously expressed, nonreceptor protein tyrosine phosphatase (PTP). It participates in signaling events downstream of receptors for growth factors, cytokines, hormones, antigens, and extracellular matrices in the control of cell growth, differentiation, migration, and death (1). Activation of SHP-2 and its association with Gab1 is critical for sustained Erk activation downstream of several growth factor receptors and cytokines (2). In addition to its role in Gab1-mediated Erk activation, SHP-2 attenuates EGF-dependent PI3 kinase activation by dephosphorylating Gab1 at p85 binding sites (3). SHP-2 becomes phosphorylated at Tyr542 and Tyr580 in its carboxy terminus in response to growth factor receptor activation (4). These phosphorylation events are thought to relieve basal inhibition and stimulate SHP-2 tyrosine phosphatase activity (5). Mutations in the corresponding gene result in a pair of clinically similar disorders (Noonan syndrome and LEOPARD syndrome) that may result from abnormal MAPK regulation (6). Alternate Names BPTP3; CFC; JMML; METCDS; MGC14433; NS1; protein tyrosine phosphatase non-receptor type 11; protein tyrosine phosphatase-2; protein tyrosine phosphatase, non-receptor type 11; Protein-tyrosine phosphatase 1D; Protein-tyrosine phosphatase 2C; PTN11; PTP-1D; PTP-2C; PTP2C; PTPN11; SH-PTP2; SH-PTP3; SHP-2; Shp2; SHPTP2; Tyrosine-protein phosphatase non-receptor type 11 Specification REACTIVITY: H M R SENSITIVITY: Endogenous MW (kDa): 72 SOURCE: Rabbit